RT Journal Article
SR Electronic
T1 MDA5-autoimmunity and Interstitial Pneumonitis Contemporaneous with the COVID-19 Pandemic (MIP-C)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.03.23297727
DO 10.1101/2023.11.03.23297727
A1 Iqbal, Khizer
A1 Sinha, Saptarshi
A1 David, Paula
A1 De Marco, Gabriele
A1 Taheri, Sahar
A1 McLaren, Ella
A1 Maisuria, Sheetal
A1 Arumugakani, Gururaj
A1 Ash, Zoe
A1 Buckley, Catrin
A1 Coles, Lauren
A1 Hettiarachchi, Chamila
A1 Smithson, Gayle
A1 Slade, Maria
A1 Shah, Rahul
A1 Marzo-Ortega, Helena
A1 Keen, Mansoor
A1 Lawson, Catherine
A1 Mclorinan, Joanna
A1 Nizam, Sharmin
A1 Reddy, Hanu
A1 Sharif, Omer
A1 Sultan, Shabina
A1 Tran, Gui
A1 Wood, Mark
A1 Wood, Samuel
A1 Ghosh, Pradipta
A1 McGonagle, Dennis
YR 2023
UL http://medrxiv.org/content/early/2023/11/05/2023.11.03.23297727.abstract
AB Background Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5+-DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 senses single-stranded RNA and is a key pattern recognition receptor for the SARS-CoV-2 virus.Methods This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between Janurary 2018-December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5+-DM outbreak.Results Sixty new anti-MDA5+, but not other MSAs surged between 2020-2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-COV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 RNA vaccines. Few (8/60) had a prior history of COVID-19, whereas 58% (35/60) had received anti-SARS-CoV-2 RNA vaccines. 25/60 cases developed ILD which rapidly progression with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong IFIH1 (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and IFIH1 strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8+ T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The IFIH1 rs1990760TT variant blunted such response.Conclusions A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-COV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes for Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Leeds, UK waived ethical approval for this work. This study was reported according to the CAse REports (CARE) guidelines [https://www.care-statement.org/]. All participants recruited granted verbal or written consent to the local treating physicians for the use of their anonymized data. An approved retrospective audit of service delivery at our institution, and a formal Institutional Research Board approval was not needed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes